| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Departments of Physiology (M.B.-Y., B.O., O.B., J.T.), Oral Biochemistry (A.G.-L.), and Pharmacology (B.S.), Göteborg University, Göteborg, Sweden S-40530; Research Centre for Endocrinology and Metabolism (M.B.-Y., B.O., O.B., O.G.P.I., C.O., J.T.), Sahlgrenska Hospital, Göteborg, Sweden S-41345; and AstraZeneca Transgenic Centre (J.T.), AstraZeneca Research and Development, Mölndal, Sweden S-43183
Address all correspondence and requests for reprints to: Jan Törnell, AstraZeneca Transgenic Centre, AstraZeneca R&D, S-43183 Mölndal, Sweden. E-mail: jan.tornell{at}astrazeneca.com
Clinical and experimental studies indicate a role for GH in mechanisms related to anhedonia/hedonia, psychic energy, and reward. Recently we showed that transgenic mice with general overexpression of bovine GH display increased spontaneous locomotor activity. In the present study, we investigated whether this behavioral change is owing to a direct action of GH in the central nervous system or to peripheral GH actions. A transgenic construct, containing the glial fibrillary acidic protein promoter directing specific expression of bovine GH to the central nervous system, was designed. The central nervous systemspecific expression of bovine GH in the glial fibrillary acidic protein-bovine GH transgenic mice was confirmed, but no effect on spontaneous locomotor activity was observed. Serum bovine GH levels were increased in glial fibrillary acidic proteinbovine GH transgenic mice but clearly lower than in transgenic mice with general overexpression of bovine GH. In contrast to the transgenic mice with general overexpression of bovine GH, glial fibrillary acidic protein-bovine GH mice did not display any difference in serum IGF-I levels. The levels of free T3 and the conversion of the free T4 to free T3 were only increased in transgenic mice with general overexpression of bovine GH, but serum corticosterone levels were similarly increased in both transgenic models. These results suggest that free T3 and/or IGF-I, affecting dopamine and serotonin systems in the central nervous system, may mediate the enhanced locomotor activity observed in transgenic mice with general overexpression of bovine GH.
This article has been cited by other articles:
![]() |
C. Ohlsson, S. Mohan, K. Sjogren, A. Tivesten, J. Isgaard, O. Isaksson, J.-O. Jansson, and J. Svensson The Role of Liver-Derived Insulin-Like Growth Factor-I Endocr. Rev., August 1, 2009; 30(5): 494 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Svensson, B. Soderpalm, K. Sjogren, J. Engel, and C. Ohlsson Liver-derived IGF-I regulates exploratory activity in old mice Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E466 - E473. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Olsson, M. Bohlooly-Y, S. M. Fitzgerald, F. Frick, A. Ljungberg, B. Ahren, J. Tornell, G. Bergstrom, and J. Oscarsson Bovine Growth Hormone Transgenic Mice Are Resistant to Diet-Induced Obesity but Develop Hyperphagia, Dyslipidemia, and Diabetes on a High-Fat Diet Endocrinology, February 1, 2005; 146(2): 920 - 930. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bohlooly-Y, B. Olsson, C. E.G. Bruder, D. Linden, K. Sjogren, M. Bjursell, E. Egecioglu, L. Svensson, P. Brodin, J. C. Waterton, et al. Growth Hormone Overexpression in the Central Nervous System Results in Hyperphagia-Induced Obesity Associated With Insulin Resistance and Dyslipidemia Diabetes, January 1, 2005; 54(1): 51 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Olsson, M. Bohlooly-Y, O. Brusehed, O. G. P. Isaksson, B. Ahren, S.-O. Olofsson, J. Oscarsson, and J. Tornell Bovine growth hormone-transgenic mice have major alterations in hepatic expression of metabolic genes Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E504 - E511. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Lemon, D.R. Boreham, and C.D. Rollo A Dietary Supplement Abolishes Age-Related Cognitive Decline in Transgenic Mice Expressing Elevated Free Radical Processes Experimental Biology and Medicine, July 1, 2003; 228(7): 800 - 810. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |